EUVIMEDEUVIMED entdecken
VergleichsstudieKohortenstudie

Comparative effectiveness of upadacitinib versus dupilumab for moderate-to-severe atopic dermatitis: A retrospective cohort study

Yan Yang, Jiaoquan Chen, Siyin Xiong, Jing Zhang, Qianru Ye, Rujun Xue, Xin Tian, Jiemin Zhong, Huilan Zhu, Aili Gao, Yumei Liu

International Immunopharmacology · 2024

DOI: 10.1016/j.intimp.2024.113383 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Yan Yang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Guangzhou Dermatology Hospital, Guangzhou, Guangdong 510095, PR China. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Janus Kinase Inhibitors, Interleukin-4 Receptor alpha Subunit. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Although efficacy and safety of Upadacitinib and Dupilumab in moderate to severe atopic dermatitis (AD) have been shown in clinical trials, real world data are still limited. The aim of this retrospective study is to indirectly compare the efficacy and safety of Upadacitinib and Dupilumab in patients with moderate to severe AD in real world practice. METHODS: A single-center retrospective cohort study was conducted. The study included patients with moderate to severe AD, who were enrolled from May 2022 to March 2024, to indirectly compare the efficacy and safety of Upadacitinib and Dupilumab over 12 weeks duration. RESULTS: Eighty-seven patients were included (46 received Upadacitinib and 41 Dupilumab). Compared with week 0, there was a significant decrease in EASI score, ADCT score and NRS score in patients of both groups in weeks 4, 8, and 12. In week 4, the reduction in EASI score, ADCT score and NRS score was significantly greater in patients of Upadacitinib group compared to those in Dupilumab group. Compared to baseline, in week 12, the decrease in IL-4, IL-13, and IL-31 level in the serum of patients in Upadacitinib group was significantly greater than that of patients in Dupilumab group. The total IgE of patients in Dupilumab group decreased significantly, while there was no significant change in patients of Upadacitinib group. Although Upadacitinib group reported more adverse events than Dupilumab group, no serious adverse events were observed. CONCLUSIONS: Both Upadacitinib and Dupilumab groups showed effective trend in patients with moderate to severe AD. Upadacitinib has better efficacy and rapid onset in the treatment of patients with moderate to severe AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicJanus Kinase InhibitorsInterleukin-4 Receptor alpha SubunitRetrospective StudiesHumansMaleFemaleYoung AdultAdultTreatment OutcomeHeterocyclic Compounds, 3-Ring

Stichwörter der Autor:innen

Atopic dermatitisDupilumabUpadacitinib

Substanzen

Janus Kinase InhibitorsInterleukin-4 Receptor alpha SubunitupadacitinibHeterocyclic Compounds, 3-Ring

Autor:innen und Institutionen

  • Department of Dermatology, Guangzhou Dermatology Hospital, Guangzhou, Guangdong 510095, PR China.
  • Department of Dermatology, Guangzhou Dermatology Hospital, Guangzhou, Guangdong 510095, PR China. Electronic address: alicegao197897@163.com.
  • Department of Dermatology, Guangzhou Dermatology Hospital, Guangzhou, Guangdong 510095, PR China. Electronic address: liuyumei1109@163.com.

Zitieren

APA

Yang, Y., Chen, J., Xiong, S., Zhang, J., Ye, Q., Xue, R., Tian, X., Zhong, J., Zhu, H., Gao, A., & Liu, Y. (2024). Comparative effectiveness of upadacitinib versus dupilumab for moderate-to-severe atopic dermatitis: A retrospective cohort study. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.113383

Vancouver

Yang Y, Chen J, Xiong S, Zhang J, Ye Q, Xue R, et al. Comparative effectiveness of upadacitinib versus dupilumab for moderate-to-severe atopic dermatitis: A retrospective cohort study. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.113383

BibTeX
@article{Yang2024,
  author = {Yang, Yan and Chen, Jiaoquan and Xiong, Siyin and Zhang, Jing and Ye, Qianru and Xue, Rujun and Tian, Xin and Zhong, Jiemin and Zhu, Huilan and Gao, Aili and Liu, Yumei},
  title = {Comparative effectiveness of upadacitinib versus dupilumab for moderate-to-severe atopic dermatitis: A retrospective cohort study},
  journal = {International Immunopharmacology},
  year = {2024},
  doi = {10.1016/j.intimp.2024.113383}
}
Kostenlos starten →